We are live on ! Find out more
IPHA

Innate Pharma
IPHA

9 hedge funds and large institutions have $1.13M invested in Innate Pharma in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.5% → 0.49% (-0%)

18% less funds holding

Funds holding: 11 → 9 (-2)

24% less capital invested

Capital invested by funds: $1.49M → $1.13M (-$363K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Optiver Holding
Optiver Holding
Netherlands
+$381K
2
UBS Group
UBS Group
Switzerland
+$3.58K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$350K
2
Millennium Management
Millennium Management
New York
-$31.4K
3
TRCT
Tower Research Capital (TRC)
New York
-$11K
4
Morgan Stanley
Morgan Stanley
New York
-$2.07K
5
Citigroup
Citigroup
New York
-$201

IPHA Hedge Fund Activity: Q1 2023 in Review

9 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2023, worth a combined $1.13M — down 24% from $1.49M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of IPHA and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Optiver Holding, adding an estimated $381K. The largest seller was Bank of America, cutting an estimated $350K.

  • 9 institutional investors held Innate Pharma (IPHA) as of Q1 2023, down from 11 in Q4 2022.
  • Funds reported $1.13M of Innate Pharma stock for Q1 2023, down 24% quarter-over-quarter.
  • 0 funds opened new Innate Pharma positions in Q1 2023 and 2 closed out, a net change of -2 holders.
  • The largest Innate Pharma buyer in Q1 2023 was Optiver Holding, an estimated $381K added.
  • The largest Innate Pharma seller in Q1 2023 was Bank of America, an estimated $350K sold.

Based on aggregated 13F filings for Q1 2023.